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ALT

:   alanine aminotransferase

APTT

:   activated partial thromboplastin time

AST

:   aspartate aminotransferase

AUC

:   area under the curve of receiver operating characteristics

CI

:   confidence interval

COVID‐19

:   2019 novel coronavirus‐infected disease

CT

:   computed tomography

OR

:   odds ratio

PII

:   pulmonary inflammation index

RT‐PCR

:   real‐time reverse‐transcription--polymerasechain‐reaction

Se

:   sensitivity

Sp

:   specificity

1. INTRODUCTION {#jmv26082-sec-0010}
===============

The outbreak of a novel coronavirus‐infected disease (COVID‐19) occurred in Wuhan, China at the end of 2019. The etiology is a novel betacoronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), and the most probable origin is bat.[^1^](#jmv26082-bib-0001){ref-type="ref"}, [^2^](#jmv26082-bib-0002){ref-type="ref"} The main clinical feature was fever, dry cough, dyspnea, myalgia, and fatigue.[^3^](#jmv26082-bib-0003){ref-type="ref"}, [^4^](#jmv26082-bib-0004){ref-type="ref"} On chest computed tomography (CT), ground‐glass opacity was the most common radiologic finding.[^5^](#jmv26082-bib-0005){ref-type="ref"} Person‐to‐person transmission has been identified at early stage.[^6^](#jmv26082-bib-0006){ref-type="ref"}, [^7^](#jmv26082-bib-0007){ref-type="ref"} The median incubation period was 5.2 days and the basic reproductive number was estimated to be 2.2.[^6^](#jmv26082-bib-0006){ref-type="ref"} People are all generally susceptible to the virus.[^8^](#jmv26082-bib-0008){ref-type="ref"}

As of 24 May 2020, 84 525 cases were recorded in China.[^9^](#jmv26082-bib-0009){ref-type="ref"} The proportion of severe and critical cases was 14% and 5%, respectively.[^10^](#jmv26082-bib-0010){ref-type="ref"} The mortality was 5.5% in China and 6.5% worldwide.[^9^](#jmv26082-bib-0009){ref-type="ref"} However, it increased to 49% among critical ill cases. As the high mortality in severe cases, early identification of the patients who would progress to severe cases is important. Therefore, we aimed to identify the risk factors collected at admission to predict the mild patients who would progress to severe cases during hospitalization.

2. METHODS {#jmv26082-sec-0020}
==========

This was a retrospective observational study collected patients with COVID‐19 from 1st January to 29th February 2020. Data were extracted from two centers of Chongqing, China. One center is in Chongqing Three Gorges Central Hospital and the other is in Chongqing Public Health Medical Center. Nasophrygeal swab or anal swab even sputum was obtained and real‐time reverse‐transcription‐polymerase chain reaction (RT‐PCR) assay for SARS‐CoV‐2 was tested. In some patients with high probability of COVID‐19, multiple tests were performed. The diagnosis of COVID‐19 was confirmed by positive RT‐PCR assay. All the patients were managed according to the protocols made by National Health Commission of China. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (No. 20200601). As the emerging infection disease and the retrospective design, the informed consent was waived.

As the aim of this study was to identify the risk factors to predict whether the patients would progress to severe cases, we only enrolled the nonsevere cases at admission. Based on protocols made by National Health Commission of China, the severe patients were defined when they meet one of three criteria: (a) dyspnea, respiratory rate \>30 breaths/min, (b) oxygen saturation \<93% in ambient air, (c) PaO~2~/FiO~2~ \< 300mm Hg.[^11^](#jmv26082-bib-0011){ref-type="ref"} Patients were followed up to discharge or became severe because some severe cases were still in hospitalization. And the time from nonsevere to severe was recorded.

We extracted the data from the medical records. Three kinds of data were collected, basic information, laboratory tests, and radiographic imaging. Basic information included age, sex, underlying disease, temperature, heart rate, and respiratory rate. Laboratory tests included white blood cell counts, lymphocyte counts, platelet counts, hemoglobin, potassium, sodium, chlorine, creatinine, blood urea nitrogen, bilirubin, C‐reactive protein, creatine kinase, prealbumin, albumin, pH, PaCO~2~, PaO~2~ and so on. The chest CT was collected and the pulmonary inflammation index (PII) was calculated. The PII = (distribution score + size score)/40 × 100%.[^12^](#jmv26082-bib-0012){ref-type="ref"} Distribution score: scored according to the lesion distribution, one score for each lung segment, and 20 scores for left and right lung. Lesion size score: scored according to whether the lesion occupied more than 50% of the lung segment volume, one score for ≥50%, and zero score for \<50%.

2.1. Statistical analysis {#jmv26082-sec-0030}
-------------------------

Data were analyzed with statistical software (SPSS Inc., Chicago, IL). Continuous variables were reported as mean value and standard deviation or median value and interquartile range when appropriate. The differences between groups were analyzed with the use of unpaired thebStudent *t* test or the Mann‐Whitney *U* test. Qualitative and categorical variables were reported as numbers and percentages, and the differences among groups were analyzed using the *χ* ^2^ tests or Fisher\'s exact tests. In the patients who progressed to severe cases, the correlation between C‐reactive protein and time from admission to progress to severe cases was calculated. A *P* value less than .05 indicated statistically significant difference.

The power of prediction whether the patients would progress to severe cases during hospitalization was tested using the area under the receiver operating characteristic curves (AUC). The distinguishing power was stratified as excellent, good, moderate, and mild when the AUC ≥ 0.9, between 0.8 and 0.9, between 0.7 and 0.8, and between 0.6 and 0.7, respectively. The optimal cutoff value was chosen by the maximum Youden index.[^13^](#jmv26082-bib-0013){ref-type="ref"} At the same time, the sensitivity (Se) and specificity (Sp) was calculated.

3. RESULTS {#jmv26082-sec-0040}
==========

We screened 397 patients for eligibility (Figure [1](#jmv26082-fig-0001){ref-type="fig"}). Forty four patients were severe cases at admission and five patients\' data were unavailable. Finally, 348 nonsevere cases at admission were enrolled in this study. Of the 348 nonsevere patients, 20 cases (5.7%) deteriorated and became severe after median 4.0 days (interquartile range, 2.3‐6.0). Of the 20 severe cases, eight received conventional oxygen therapy, nine received noninvasive ventilation, two received high flow nasal cannula, and one received intubation. The patients who progressed to severe cases were older than nonsevere cases (Table [1](#jmv26082-tbl-0001){ref-type="table"}). They also had higher temperature, higher heart rate, higher PII, higher creatinine, higher alanine aminotransferase (ALT), higher aspartate aminotransferase (AST), higher C‐reactive protein, higher procalcitonin, higher creatine kinase, higher pH, lower prealbumin, lower PaCO~2~, lower platelet counts, lower CD3 counts, lower CD4 counts, lower potassium, lower sodium, and lower chlorine.

![The flow chart](JMV-9999-na-g001){#jmv26082-fig-0001}

###### 

Baseline data

                                      Nonsevere cases N = 328   Progress to severe cases N = 20   *P*
  ----------------------------------- ------------------------- --------------------------------- -------
  Age, y                              44 ± 15                   58 ± 15                           \<.01
  Female sex                          158 (48%)                 6 (30%)                           .17
  Temperature, °C                     37.1 ± 0.7                37.6 ± 1.0                        .01
  Heart rate, beats/min               88 ± 12                   97 ± 10                           \<.01
  Respiratory rate, breaths/min       20 ± 1                    20 ± 1                            .4
  PII                                 18 ± 13                   37 ± 18                           \<.01
  Comorbidity                                                                                     
  Hypertension                        23 (7%)                   4 (20%)                           .06
  Diabetes mellitus                   9 (3%)                    2 (10%)                           .13
  Chronic kidney disease              1 (0.3%)                  0 (0%)                            \>.99
  Chronic liver disease               9 (3%)                    2 (10%)                           .13
  Chronic heart disease               5 (2%)                    0 (0%)                            \>.99
  Chronic respiratory disease         3 (1%)                    0 (0%)                            \>.99
  Laboratory tests                                                                                
  White blood cell counts, ×10^9^/L   5.5 ± 2.1                 4.6 ± 1.6                         .08
  Neutrophil percentage, %            63 ± 12                   66 ± 11                           .39
  Lymphocyte counts, ×10^9^/L         1.3 (1.0‐1.7)             1.1 (0.9‐4.3)                     .9
  Lymphocyte percentage, %            27 ± 11                   29 ± 16                           .48
  Neutrophil to lymphocyte ratio      3.1 ± 2.6                 2.9 ± 1.7                         .69
  Platelet counts, ×10^9^/L           196 ± 75                  127 ± 34                          \<.01
  Hemoglobin, mg/dL                   135 ± 18                  136 ± 15                          .9
  Potassium, mmol/L                   4.1 ± 0.5                 3.8 ± 0.5                         .01
  Sodium, mmol/L                      139 ± 3                   135 ± 3                           \<.01
  Chlorine, mmol/L                    103 ± 4                   99 ± 3                            \<.01
  Creatinine, μmol/L                  67 ± 18                   81 ± 27                           \<.01
  Blood urea nitrogen, mmol/L         4.0 ± 1.4                 4.1 ± 2.6                         .74
  Total bilirubin, μmol/L             14.2 ± 10.2               13.4 ± 6.6                        .74
  ALT, U/L                            28 ± 21                   43 ± 31                           \<.01
  AST, U/L                            28 ± 22                   45 ± 34                           \<.01
  C‐reactive protein, mg/L            7 (2‐21)                  47 (21‐64)                        \<.01
  Procalcitonin, ng/mL                0.03 (0.02‐0.05)          0.05 (0.04‐0.10)                  \<.01
  Creatine kinase, U/L                65 (45‐94)                161 (68‐330)                      .01
  PT, seconds                         11.5 ± 2.0                12.1 ± 2.4                        .27
  APTT, seconds                       33.2 ± 8.1                37.8 ± 8.1                        .02
  FIB, μg/ml                          3.9 ± 1.0                 4.6 ± 0.8                         .02
  D‐dimer, mg/L                       0.18 (0.11‐0.31)          0.26 (0.16‐0.55)                  .07
  Prealbumin, mg/L                    227 ± 77                  148 ± 54                          \<.01
  Albumin, g/L                        43 ± 6                    41 ± 3                            .13
  Arterial blood gas tests                                                                        
  pH                                  7.40 ± 0.04               7.45 ± 0.04                       \<.01
  PaCO~2~, mm Hg                      42 ± 5                    37 ± 4                            \<.01
  PaO~2~, mm Hg                       88 ± 20                   84 ± 25                           .54
  Lac, mmol/L                         2.2 ± 0.9                 2.0 ± 0.6                         .41
  Lymphocyte subsets                                                                              
  CD3, counts/μL                      928 ± 471                 618 ± 274                         .05
  CD4, counts/μL                      484 ± 257                 320 ± 153                         .02
  CD8, counts/μL                      329 ± 186                 243 ± 148                         .09
  CD4/CD8                             1.7 ± 0.9                 1.3 ± 0.6                         .19

Abbreviations: ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; FIB, fibrinogen; PII, pulmonary inflammation index; PT, prothrombin time.
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The AUC was ≥0.80 in PII, platelet counts, sodium, C‐reactive protein, prealbumin, and PaCO~2~ to predict whether the patients would progress to severe cases, indicating that the distinguishing power was good (Table [2](#jmv26082-tbl-0002){ref-type="table"}). The age, heart rate, chlorine, ALT, AST, procalcitonin, creatine kinase, pH, CD3 counts, and CD4 counts reached moderate distinguishing power. The potassium, creatinine temperature, and D‐dimer reached mild distinguishing power.

###### 

Prediction of progression to severe cases using the variables collected at admission

                                  AUC (95% CI)       Cutoff value   Se, %   Sp, %
  ------------------------------- ------------------ -------------- ------- -------
  Good distinguishing power                                                 
  PII                             0.80 (0.74‐0.85)   \>25%          75      76
  Platelet counts, ×10^9^/L       0.81 (0.76‐0.85)   ≤174           100     56
  Sodium, mmol/L                  0.82 (0.78‐0.86)   ≤138           94      62
  C‐reactive protein, mg/L        0.82 (0.77‐0.86)   \>18           83      73
  Prealbumin, mg/L                0.80 (0.73‐0.85)   ≤151           64      85
  PaCO~2~, mm Hg                  0.80 (0.74‐0.86)   ≤41            93      58
  Moderate distinguishing power                                             
  Age, y                          0.75 (0.70‐0.80)   \>53           65      75
  Heart rate, beats/min           0.72 (0.67‐0.76)   \>90           72      64
  Chlorine, mmol/L                0.78 (0.73‐0.82)   ≤101           72      7
  ALT, U/L                        0.72 (0.67‐0.76)   \>22           89      54
  AST, U/L                        0.71 (0.65‐0.75)   \>34           61      81
  Procalcitonin, ng/mL            0.74 (0.69‐0.78)   \>0.04         79      65
  Creatine kinase, U/L            0.75 (0.70‐0.80)   \>118          61      82
  pH                              0.75 (0.69‐0.81)   \>7.40         87      49
  CD3, counts/μL                  0.71 (0.63‐0.78)   ≤553           67      77
  CD4, counts/μL                  0.70 (0.64‐0.76)   ≤403           86      55
  Mild distinguishing power                                                 
  Potassium, mmol/L               0.68 (0.63‐0.73)   ≤3.7           61      79
  Creatinine, μmol/L              0.64 (0.59‐0.69)   \>68           6       58
  Temperature, °C                 0.65 (0.59‐0.70)   \>37.3         59      74
  D‐dimer, mg/L                   0.64 (0.57‐0.70)   \>0.14         88      39

Abreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve of receiver operating characteristics; CI, confidence interval; PII, Pulmonary inflammation index; Se, sensitivity; Sp, specificity.
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When the PII ≤ 25% was set as a reference, the odds ratio (OR) was 6.5 in patients with PII between 26% and 50% and 38.7 in those with PII \> 50% (Table [3](#jmv26082-tbl-0003){ref-type="table"}). When the platelet counts \>150 × 10^9^/L was set as a reference, the OR was 4.7 and 14.5 in patients with platelet counts between 101 to 150 × 10^9^/L and ≤100 × 10^9^/L, respectively. Similar ORs of progression to severe cases were found in other variables.

###### 

Odds ratio of progression to severe cases stratified by different cutoff values

                              OR (95% CI)        *P*
  --------------------------- ------------------ -------
  PII                                            
  ≤25% versus 26%‐50%         6.5 (2.1‐20.5)     \<.01
  ≤25% versus \>50%           38.7 (8.2‐182.1)   \<.01
  Platelet counts, ×10^9^/L                      
  \>150 versus 101‐150        4.7 (1.4‐15.3)     .01
  \>150 versus ≤100           14.5 (3.9‐55.8)    \<.01
  Sodium, mmol/L                                 
  \>138 versus 135‐138        12.9 (2.8‐58.7)    \<.01
  \>138 versus \<135          21.7 (3.7‐126.2)   \<.01
  C‐reactive protein, mg/L                       
  ≤20 versus 21‐40            6.1 (1.5‐25.7)     .02
  ≤20 versus \>40             13.4 (4.0‐45.0)    \<.01
  Prealbumin, mg/L                               
  \>150 versus ≤150           6.6 (1.9‐23.1)     \<.01
  PaCO~2~, mm Hg                                 
  \<35 versus ≥35             11.2 (3.1‐40.5)    \<.01
  Age, y                                         
  ≤55 versus 56‐65            3.0 (0.9‐10.5)     .09
  ≤55 verssus \>65            10.9 (3.7‐31.6)    \<.01
  Heart rate, beats/min                          
  ≤90 versus 91‐100           4.0 (1.2‐13.1)     .02
  ≤90 versus \>100            5.9 (1.7‐20.1)     \<.01
  Chlorine, mmol/L                               
  \>100 versus ≤100           7.3 (2.5‐21.0)     \<.01
  ALT, U/L                                       
  ≤40 versus \>40             3.3 (1.2‐8.9)      .02
  AST, U/L                                       
  ≤40 versus 41‐60            4.4 (1.3‐15.0)     .03
  ≤40 versus \>60             5.8 (1.7‐20.2)     .01
  Procalcitonin, ng/mL                           
  ≤0.03 versus 0.04‐0.10      4.5 (1.4‐14.4)     .01
  ≤0.03 versus \>0.10         10.7 (2.4‐46.4)    \<.01
  Creatine kinase, U/L                           
  ≤150 versus 151‐300         4.0 (1.0‐15.9)     .07
  ≤150 versus \>300           25.1 (7.0‐90.1)    \<.01
  pH                                             
  \>7.45 versus ≤7.45         5.3 (1.7‐16.3)     \<.01
  CD3, counts/μL                                 
  ≤553                        6.6 (1.6‐28.1)     .01
  CD4, counts/μL                                 
  ≤403                        7.4 (1.6‐33.7)     \<.01
  Potassium, mmol/L                              
  \>3.7 versus 3.5‐3.7        4.2 (1.2‐14.8)     .04
  \>3.7 versus 5              5.3 (1.7‐16.1)     \<.01
  Creatinine, μmol/L                             
  ≤100 versus \>100           6.7 (1.9‐23.4)     \<.01
  Temperature (°C)                               
  ≤37.3 versus \>37.3         4.0 (1.5‐10.9)     \<.01

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; OR, odds ratio; PII, pulmonary inflammation index.
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In the patients who progressed to severe cases, the negative correlation was found between C‐reactive protein and time from admission to severe cases (Figure [2](#jmv26082-fig-0002){ref-type="fig"}). The correlative coefficient was −0.64. Patients who progressed to severe cases less than 4 days had higher C‐reactive protein than those more than 4 days (61 ± 28 vs 27 ± 21 mg/L; *P* = .01).

![Correlation between C‐reactive protein and the time from nonsevere to progress to severe cases](JMV-9999-na-g002){#jmv26082-fig-0002}

4. DISCUSSION {#jmv26082-sec-0050}
=============

To the best of our knowledge, this is the first study to report so many variables collected at admission to predict the patients who would progress to severe cases during hospitalization. PII, platelet counts, sodium, C‐reactive protein, prealbumin, and PaCO~2~ reached good distinguishing power to predict progression to severe cases. The age, heart rate, chlorine, ALT, AST, procalcitonin, creatine kinase, pH, CD3 counts, and CD4 counts reached moderate distinguishing power. And the potassium, creatinine temperature and D‐dimer reached mild distinguishing power. In the patients who progressed to severe cases, the C‐reactive protein was negative correlation with the time from admission to progress to severe cases.

The time from disease onset to dyspnea was median 8 days, to development of acute respiratory distress syndrome was median 9 days, and to admission to intensive carfe unit was median 10.5 days.[^3^](#jmv26082-bib-0003){ref-type="ref"} At the early stage, the 28‐day mortality was 61.5% among the critically ill cases.[^14^](#jmv26082-bib-0014){ref-type="ref"} As the fast development and high mortality, early identification of the patients who would progress to severe cases is potential to reduce mortality. Our study originally reported that six variables collected at admission had good predictive power, 10 variables had moderate predictive power, and four variables had mild predictive power. These variables can help the clinical physicians to identify the potential cases who would progress to severe cases. Patients with these variables should be paid more attention even applied intensive care to avoid progression to severe cases.

Abnormalities on chest CT has been found in the patients with COVID‐19. The major findings were ground‐grass opacity in 86% cases, bilateral distribution in 76% cases, peripheral distribution in 33%, consolidation in 29% cases, and crazy paving in 19% of cases.[^15^](#jmv26082-bib-0015){ref-type="ref"} However, this is only a descriptive study. These findings are difficult to predict the disease severity. In another study focused on COVID‐19, a semiquantitative score, PII, was used to assess the abnormalities on chest CT.[^12^](#jmv26082-bib-0012){ref-type="ref"} This study showed the PII was correlated with the values of lymphocyte count, monocyte count, C‐reactive protein, procalcitonin, and temperature. It means that the PII is correlated with the severity of the disease. In our study, we found that PII had good predictive power to assess the disease progression. Compared with the patients with PII ≤ 25%, the risk of progression to severe cases increased to 6.5 folds in patients with PII between 26% and 50% and further increased to 38.7 folds in those with PII more than 50%. Using the PII of 25% as a cutoff value, the Se and Sp to predict disease progression was 75% and 76%, respectively. Therefore, the PII was a good variable to stratify the severity of the patients with COVID‐19.

In our study, we found that the prealbumin but not albumin was a risk factor to predict the patients who would progress to severe cases. The half time of albumin was approximately 20 days but the prealbumin was only 2 days.[^16^](#jmv26082-bib-0016){ref-type="ref"} As the time from disease onset to admission was median 7 days,[^3^](#jmv26082-bib-0003){ref-type="ref"} the albumin did not reflect the real status of the nutrition. In our study, patients with prealbumin less than 150 mg/L were 6.6 folds to progress to severe cases compared with those with prealbumin more than 150 mg/L. As the COVID‐19 had short incubation period, the prealbumin is a good risk factor to predict whether the patients would progress to severe cases.

The Middle East respiratory syndrom coronavirus is similar with SARS‐CoV‐2, and they have similar clinical features.[^17^](#jmv26082-bib-0017){ref-type="ref"} In patients with severe Middle East respiratory syndrome coronavirus pneumonia, increasing in C‐reactive protein levels is correlated with clinical deterioration.[^18^](#jmv26082-bib-0018){ref-type="ref"} However, the correlation between C‐reactive protein and disease severity is unclear in patients with COVID‐19. In our study, we found that patients with higher level of C‐reactive protein were more likely to progress to severe cases, and the level of C‐reactive protein was negative correlated with the time from admission to progression to severe cases. These findings can help the clinical staffs to stratify the patients.

Our study has several limitations. First, this is a retrospective observational study. Some participants had incomplete laboratory tests at admission due to the shortage of medical staffs and lack of management protocols at the early stage. Second, the patients were only followed up to discharge or became severe. It is unable for us to assess the risk factors for poor outcomes. Third, our study found that hypertension was associated with progression to severe cases though it did not reach statistical significance (*P* = .06). This result was confirmed by another study.[^19^](#jmv26082-bib-0019){ref-type="ref"} Therefore, both the laboratory tests and comorbidity should be considered when the patients with COVID‐19 were managed.

5. CONCLUSIONS {#jmv26082-sec-0060}
==============

Our study reported 19 potential variables collected at admission to predict the patients who would progress to severe cases. Six variables showed good predictive power, 10 showed moderate predictive power, and four showed mild predictive power. C‐reactive protein is negative correlative with the time from nonsevere to progress to severe cases.
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